— Know what they know.
Not Investment Advice

QLGN NASDAQ

Qualigen Therapeutics, Inc.
1W: +4.4% 1M: -6.3% 3M: +18.5% 1Y: -39.2% 3Y: -96.8% 5Y: -99.9%
$3.21
Last traded 2025-12-15 — delisted
NASDAQ · Healthcare · Biotechnology · $5.4M mcap · 2M float · 156.06% daily turnover · Short 48% of daily vol

Balance Sheet Trends

Total Assets
$31M +567.4% ▲
5Y CAGR: +1.4%
Total Liabilities
$3M +65.8% ▲
5Y CAGR: -21.0%
Shareholders Equity
$28M +943.3% ▲
5Y CAGR: +8.8%
Cash & Investments
$19M +1545.9% ▲
5Y CAGR: -4.2%
Total Debt
$142K +0.0% ▲
5Y CAGR: -25.8%
Net Debt
-$19M -1533.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$18M$3M$402K$1M$19M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$18M$3M$402K$1M$19M
Net Receivables$822K$539K$0$2M$343K
Inventory$1M$2M$0$0$0
Other Current Assets$4K$4M$0$31K$11M
Total Current Assets$21M$11M$1M$5M$31M
Property, Plant & Equip.$2M$26K$0$0$0
Goodwill & Intangibles$171K$6M$0$0$315K
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$18K$2M$866K$2K$10K
Total Non-Current Assets$2M$8M$866K$2K$325K
Total Assets$23M$19M$2M$5M$31M
— Liabilities —
Accounts Payable$886K$620K$2M$2M$1M
Short-Term Debt$0$60K$1M$0$142K
Deferred Revenue$135K$116K$0$0$0
Other Current Liabilities$2M$7M$63K$269K$3M
Total Current Liabilities$5M$9M$4M$2M$3M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$2M$2M$0$0$0
Total Liabilities$6M$10M$4M$2M$3M
— Equity —
Common Stock$35K$42K$43K$65K$70K
Retained Earnings-$85M-$103M-$117M-$123M-$140M
Accumulated OCI$0$51K$0$0$0
Total Stockholders Equity$17M$7M-$2M$3M$28M
Total Liabilities & Equity$23M$19M$2M$5M$31M
— Key Metrics —
Total Debt$2M$2M$1M$0$142K
Net Debt-$16M-$1M$897K-$1M-$19M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms